Entry Detail


General Information

Database ID: LDA0006524
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:SNHG8
Full Name:small nucleolar RNA host gene 8
Category:LncRNA
Species:Homo sapiens
Synonyms:LINC00060|NCRNA00060
Chromosome:4
Strand:+
Coordinate:
Start Site(bp):118278762End Site(bp):118279823
External Links:
Ensembl ID:ENSG00000269893
Ensembl Transcript ID:ENSG00000269893
Entrez Gene:100093630.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:36   
More Information
Causal Disease Number:32
Network:
Top Causal Diseases:
Breast Neoplasms  (Score: 0.999358)
Breast Neoplasms  (Score: 0.999358)
Nasopharyngeal carcinoma  (Score: 0.985791)
Nasopharyngeal carcinoma  (Score: 0.985791)
Osteosarcoma  (Score: 0.731059)
Lymphoma, Large B-Cell, Diffuse  (Score: 0.731059)
Parkinson Disease  (Score: 0.731059)
Ovarian Neoplasms  (Score: 0.731059)
Colorectal Neoplasms  (Score: 0.731059)
Esophageal Neoplasms  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:14330D010300
Disease Name:Parkinson's diseaseParkinson Disease
Category:Disease OntologyMeSH
Type:Nervous System Diseases
Define:A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Alias:Parkinson disease//paralysis agitansParkinson Disease//Idiopathic Parkinson's Disease//Lewy Body Parkinson's Disease//Parkinson's Disease, Idiopathic//Parkinson's Disease, Lewy Body//Parkinson Disease, Idiopathic//Parkinson's Disease//Idiopathic Parkinson Disease//Lewy Body Parkinson Disease//Primary Parkinsonism//Parkinsonism, Primary//Paralysis Agitans

 

Disease Association Statistics

Total Associated ncRNA Number:84   
More Information
Causal ncRNA Number:74
Network:
Top Causal ncRNAs:
NEAT1  (Score: 1)
NEAT1  (Score: 1)
Neat1  (Score: 0.999893)
Neat1  (Score: 0.999893)
Snhg14  (Score: 0.985791)
SNHG1  (Score: 0.985791)
hsa_circ_0004381  (Score: 0.985791)
Snhg14  (Score: 0.985791)
MEG3  (Score: 0.985791)
SNHG1  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:CCK8//qRT-PCR//RIP
Weak Evidence:

 

Reference

[1] PubMed ID:36401052
Disease Name:Parkinson Disease
Sample: PD mice, MN9D cells
Dysfunction Pattern:Interaction(miR-421-3p, and miR-421-3p targeted SNX8)
Validated Method:CCK8//qRT-PCR//RIP
Description:SNHG8 and SNX8 expression levels were decreased while miR-421-3p expression level was increased in the SN of PD mice and rotenone-treated MN9D cells. Mechanistically, SNHG8 bound to miR-421-3p, and miR-421-3p targeted SNX8. Overexpressed SNHG8 downregulates miR-421-3p to alleviate rotenone-induced dopaminergic neuron injury in PD via upregulating SNX8.
Causality:Yes
Causal Description: Upregulated SNHG8 ameliorated dopaminergic neuron damage and locomotor dysfunction in PD mice. Meanwhile, upregulated SNHG8 enhanced viability, diminished apoptosis, and alleviated mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy in rotenone-treated MN9D cells.
Clinical-realted Application: